SPECIALTY GUIDELINE MANAGEMENT

Revatio (sildenafil tablets and oral suspension)
Sildenafil tablets (generic)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indication

Sildenafil/Revatio is indicated for the treatment of pulmonary arterial hypertension (World Health Organization [WHO] Group 1) in adults to improve exercise ability and delay clinical worsening.

Limitation of use: Adding sildenafil to bosentan therapy does not result in any beneficial effect on exercise capacity.

B. Compendial Use

Secondary Raynaud’s phenomenon (Tablets only)

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

A. Pulmonary Arterial Hypertension

Authorization of 12 months may be granted for treatment of PAH when ALL of the following criteria are met:

1. Member has PAH defined as WHO Group 1 class of pulmonary hypertension (refer to Appendix).
2. PAH was confirmed by either criterion (i) or criterion (ii) below:
   i. Pretreatment right heart catheterization with all of the following results:
      a. mPAP ≥ 25 mmHg
      b. PCWP ≤ 15 mmHg
      c. PVR > 3 Wood units
   ii. For infants less than one year of age with any of the following conditions, PAH was confirmed by Doppler echocardiogram if right heart catheterization cannot be performed:
      a. Post cardiac surgery
      b. Chronic heart disease
      c. Chronic lung disease associated with prematurity
      d. Congenital diaphragmatic hernia

B. Secondary Raynaud’s Phenomenon

Authorization of 12 months may be granted for treatment of secondary Raynaud’s phenomenon when the patient has had an inadequate response to one of the following medications:

1. Calcium channel blockers
2. Angiotensin receptor blockers
3. Selective serotonin reuptake inhibitors
4. Alpha blockers
5. Topical nitrates

III. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for members with an indication listed in Section II who are currently receiving the requested medication through a paid pharmacy or medical benefit, and who are experiencing benefit from therapy as evidenced by disease stability or disease improvement.

IV. APPENDIX

WHO Classification of Pulmonary Hypertension

1 PAH
  1.1 Idiopathic (PAH)
  1.2 Heritable PAH
  1.3 Drug- and toxin-induced PAH
  1.4. PAH associated with:
      1.4.1 Connective tissue diseases
      1.4.2 HIV infection
      1.4.3 Portal hypertension
      1.4.4 Congenital heart diseases
      1.4.5 Schistosomiasis
  1.5 PAH long-term responders to calcium channel blockers
  1.6 PAH with overt features of venous/capillaries (PVOD/PCH) involvement
  1.7 Persistent PH of the newborn syndrome

2 PH due to left heart disease
  2.1 PH due to heart failure with preserved LVEF
  2.2 PH due to heart failure with reduced LVEF
  2.3 Valvular heart disease
  2.4 Congenital/acquired cardiovascular conditions leading to post-capillary PH

3 PH due to lung diseases and/or hypoxia
  3.1 Obstructive lung disease
  3.2 Restrictive lung disease
  3.3 Other lung disease with mixed restrictive/obstructive pattern
  3.4 Hypoxia without lung disease
  3.5 Developmental lung disorders

4 PH due to pulmonary artery obstruction
  4.1 Chronic thromboembolic PH
  4.2 Other pulmonary artery obstructions
      4.2.1 Sarcoma (high or intermediate grade) or angiosarcoma
      4.2.2 Other malignant tumors
      Renal carcinoma
      Uterine carcinoma
      Germ cell tumours of the testis
      Other tumours
4.2.3 Non-malignant tumours
Uterine leiomyoma
4.2.4 Arteritis without connective tissue disease
4.2.5 Congenital pulmonary artery stenosis
4.2.6 Parasites
Hydatidosis

5 PH with unclear and/or multifactorial mechanisms
5.1 Hematologic disorders: Chronic hemolytic anemia, myeloproliferative disorders
5.2 Systemic and metabolic disorders: Pulmonary Langerhans cell histiocytosis, Gaucher disease, glycogen storage disease, neurofibromatosis, sarcoidosis
5.3 Others: chronic renal failure with or without hemodialysis, fibrosing mediastinitis
5.4 Complex congenital heart disease

V. REFERENCES


